View clinical trials related to Idiopathic Pulmonary Fibrosis.
Filter by:Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of subcutaneous Interferon gamma-1b. The study duration will be 5 years.
- Purpose: A phase 3, randomized, double-blind, placebo-controlled trial to determine the efficacy and safety of 200 µg of recombinant Interferon gamma-1b administered by subcutaneous (SC) injection, compared with placebo, in patients with IPF - Enrollment: Approximately 800 patients will be enrolled from approximately 80 centers in North America and Europe - Randomization: 2:1 active-to-placebo ratio - Duration: at least 2 years active drug or placebo (rescue therapy will be permitted for patients who meet predefined criteria)
Study GIPF-003 is a Phase 3b study designed to define better therapeutic use of IFN-gamma 1b in patients wtih IPF. The study will be conducted primarily in Europe and will enroll 210 patients.